Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7633659 | 0.85 | MEN1 (0.46) | ALDH1A1LMNAMAPTPKMHTT | |
| SCHEMBL7642686 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL7634605 | 0.83 | CHRM2 (0.50) | ALDH1A1KMT2AADORA3 | |
| SCHEMBL7642354 | 0.81 | MAPT (0.51) | ALDH1A1LMNAMAPTSMN1; SMN2PKM | |
| SCHEMBL7638589 | 0.81 | TLR4 (0.41) | ALDH1A1LMNAMAPTGAAKMT2A | |
| SCHEMBL7633127 | 0.79 | MAPT (0.49) | ALDH1A1LMNAMAPTSMN1; SMN2PKM | |
| SCHEMBL7642317 | 0.78 | MAPT (0.46) | ALDH1A1LMNAMAPTSMN1; SMN2PKM | |
| SCHEMBL7641782 | 0.76 | MAPT (0.47) | ALDH1A1LMNAMAPTSMN1; SMN2PKM | |
| SCHEMBL7636468 | 0.75 | GAA (0.46) | ALDH1A1LMNAMAPTGAAKMT2A | |
| SCHEMBL7633650 | 0.75 | MAPT (0.47) | ALDH1A1LMNAMAPTSMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6340772-B2 | AROMATIZATION OF CYCLOHEXENONE DERIVATIVES VIA (CHLORO)CYCLOHEXADIENE | NIPPON KAYAKU CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| US-20010020112-A1 | Process for preparing (hetero) aromatic substituted benzene derivatives | TOYA TETSUYA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-6271418-B1 | AROMATIZATION OF CYCLOHEXENONE DERIVATIVES VIA (CHLORO)CYCLOHEXADIENE DERIVATIVES. | NIPPON KAYAKU CO., LTD. (JP) | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020112-A1 | Process for preparing (hetero) aromatic substituted benzene derivatives | AHR, CYP3A4, CYP4B1 | ALDH1A1 1596/4885LMNA 1787/4885MAPT 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.